Wet Age-Related Macular Degeneration (Wet AMD) – Market Insight, Epidemiology And Market Forecast

Key Findings

• Wet AMD Market size projection: As per DelveInsight’s analysis, the total market size of Wet Age-Related Macular Degeneration in the 7MM is expected to grow from approximately USD 7,783 million in 2023 to a significantly higher valuation by 2034, with the US market leading at USD 2,599 million and projected to rise at a CAGR of 6.6% by 2034.

• Wet AMD Market Drivers: Key market drivers of Wet Age-Related Macular Degeneration include aging population demographics, innovative anti-VEGF therapies with extended dosing intervals, increased screening and early detection programs, improved treatment accessibility through value-based reimbursement models, and the development of sustained-release drug delivery systems to reduce treatment burden.

• Wet AMD Epidemiology: The report provides the total Wet Age-Related Macular Degeneration potential pool of nearly 40 million diagnosed prevalent cases of Age-Related Macular Degeneration in the 7MM in 2023, with the US accounting for approximately 18 million cases. Age-specific segmentation shows the 70-79 age group most affected, with approximately 406 thousand Wet AMD cases in the US.

• Key Wet AMD companies: Leading Wet Age-Related Macular Degeneration companies, such as Regeneron Pharmaceuticals, Novartis, Roche/Genentech, Kodiak Sciences, Opthea Limited, REGENXBIO, Pfizer, and emerging players include Sanofi and Alcon, among others.

• Wet AMD Pipeline assets: Some of the key Wet Age-Related Macular Degeneration drugs in the pipeline include Sozinibercept (OPT-302) by Opthea, KSI-501 by Kodiak Sciences, SAR446597 by Sanofi for geographic atrophy, RGX-314 by REGENXBIO, and KSI-101 by Kodiak Sciences for macular edema secondary to inflammation.

• Recent developments: In 2025, significant regulatory developments have shaped the wet AMD landscape.

  • The FDA issued a complete response letter (CRL) to Outlook Therapeutics for bevacizumab-vikg (ONS-5010) in August 2025, citing lack of efficacy evidence.

  • Regeneron faced FDA review delays for Eylea HD extended dosing applications due to manufacturing site inspections. Notably, Opthea discontinued sozinibercept development after Phase 3 COAST and ShORe trials failed to meet primary endpoints in March 2025.

  • Susvimo received FDA approval for diabetic retinopathy treatment in May 2025, marking the first continuous delivery system with 9-month refill intervals.

  • The industry also witnessed significant M&A activity with Novartis acquiring Tourmaline Bio for $1.4 billion in September 2025, expanding cardiovascular therapeutics but highlighting the interconnected nature of inflammation-based diseases affecting retinal conditions.

Discover more recent developments on FDA approvals, clinical trial results, and M&A activity impacting the global retinal therapeutics landscape.

Wet Age-Related Macular Degeneration Market Intelligence

The Wet Age-Related Macular Degeneration market represents a critical therapeutic area within ophthalmology, characterized by substantial unmet medical needs and significant commercial opportunity. The market size of USD 7,783 million in 2023 underscores the substantial economic burden of this vision-threatening condition, which primarily affects individuals over 50 years of age and is characterized by abnormal blood vessel growth beneath the retina leading to severe vision loss.

According to Delveinsight’s comprehensive Wet Age-Related Macular Degeneration (Wet AMD) – Market Insight, Epidemiology And Market Forecast report, the United States dominates the wet AMD market landscape, accounting for approximately 33% of the total 7MM market share with USD 2,600 million in 2023. This leadership position reflects advanced healthcare infrastructure, comprehensive insurance coverage, and early adoption of innovative therapies. The projected CAGR of 6.6% through 2034 demonstrates robust growth potential driven by demographic trends and therapeutic innovation. Among European markets, Germany leads with USD 1,313 million, followed by significant markets in France, Italy, and the United Kingdom, while Japan contributes USD 1,163 million with an expected CAGR of 2.6%.

The wet AMD market is propelled by several fundamental drivers that ensure sustained growth. The aging global population represents the primary demographic catalyst, as AMD prevalence increases exponentially with age. Innovative therapies, particularly anti-VEGF treatments with extended dosing intervals, address critical treatment burden concerns while maintaining efficacy. Increased screening programs and enhanced diagnostic capabilities through optical coherence tomography (OCT) and fluorescein angiography enable earlier detection and intervention. Additionally, evolving reimbursement landscapes with growing emphasis on value-based care models facilitate broader patient access to life-changing treatments.

The geographical analysis reveals significant geographical variations in market dynamics and treatment patterns. The US market benefits from comprehensive Medicare coverage for intravitreal injections and innovative payment models that support premium pricing for differentiated therapies. European markets demonstrate heterogeneous pricing and access patterns, with Germany and France leading in market size due to population demographics and healthcare system robustness. Japan presents unique opportunities with its rapidly aging population and established ophthalmic care infrastructure, though cultural factors and regulatory pathways influence adoption patterns differently than Western markets.

Furthermore, the epidemiological foundation of the wet AMD market reveals approximately 40 million diagnosed prevalent cases of AMD across the 7MM, with wet AMD representing the more severe but less common form compared to dry AMD. Age-specific analysis demonstrates peak incidence in the 70-79 age group, with approximately 406 thousand cases in the US alone. Gender distribution and geographic variations provide important insights for market access strategies and clinical development programs. The transition from dry to wet AMD and the bilateral nature of the disease progression create complex patient journey considerations that influence treatment planning and market dynamics.

Access detailed wet AMD market sizing, competitive intelligence, and 10-year growth projections across 7 major markets with patient-based epidemiological modeling.

Wet Age-Related Macular Degeneration Competitive Landscape

The wet AMD treatment competitive landscape is dominated by established anti-VEGF therapies while experiencing significant innovation through next-generation delivery systems and novel mechanisms of action. Key players include Regeneron Pharmaceuticals with EYLEA (aflibercept), which held the highest market share of approximately USD 4,276 million in the 7MM in 2023, demonstrating the commercial success of differentiated anti-VEGF therapy.

EYLEA (aflibercept) by Regeneron Pharmaceuticals maintains market leadership through superior efficacy profile and flexible dosing regimens, with FDA approval dating to November 2011 and subsequent global regulatory approvals. The drug functions as a soluble decoy receptor inhibiting VEGF-A and PlGF, with standard dosing of 2mg every 4 weeks initially, then every 8 weeks. LUCENTIS (ranibizumab) by Roche/Genentech represents the pioneering anti-VEGF therapy with established safety profile and extensive real-world experience. BEOVU (brolucizumab) by Novartis offers enhanced dosing convenience with up to 12-week intervals, addressing treatment burden concerns. AVASTIN (bevacizumab) continues as an off-label but widely used option, particularly in cost-sensitive markets.

Some of the next-generation innovations include VABYSMO (faricimab) by Roche representing breakthrough bispecific antibody technology, simultaneously targeting VEGF-A and angiopoietin-2 pathways for potentially superior durability and efficacy. Susvimo (ranibizumab injection) by Genentech introduces revolutionary continuous delivery through the Port Delivery Platform, offering sustained drug release with refills every 6-9 months, dramatically reducing injection frequency and improving patient quality of life.

The Wet Age-Related macular degeneration pipeline reflects intense innovation focused on addressing current therapy limitations. Sozinibercept (OPT-302) by Opthea, despite recent Phase 3 setbacks, demonstrated novel VEGF-C/D inhibition approach designed for combination therapy to achieve superior visual gains. KSI-501 by Kodiak Sciences represents innovative bispecific conjugate targeting both VEGF and IL-6 pathways, currently in Phase 3 DAYBREAK study with enhanced 50mg/mL formulation designed for 8-week dosing intervals. RGX-314 by REGENXBIO advances gene therapy approaches for sustained anti-VEGF expression, potentially transforming treatment paradigms through single administration.

Recent regulatory activities highlight both opportunities and challenges in the competitive landscape. FDA’s complete response letter for bevacizumab-vikg demonstrates regulatory scrutiny for biosimilar and reformulated products. Extended review timelines for Eylea HD applications reflect manufacturing complexities for next-generation formulations. The discontinuation of sozinibercept development underscores clinical and commercial risks in competitive markets while validating the difficulty of achieving differentiation in established therapeutic areas.

Discover 75+ wet AMD pipeline assets in development, Phase III trial timelines, and regulatory milestone tracking for next-generation wet AMD therapeutics.

Wet Age-Related Macular Degeneration Market Drivers and Barriers

Despite significant therapeutic advances, wet AMD treatment faces substantial unmet needs that drive continued innovation and market growth. Current anti-VEGF therapies require frequent intravitreal injections, creating a significant treatment burden for patients and healthcare systems. Many patients experience suboptimal visual outcomes, with incomplete response rates and disease progression over time. The need for longer-acting therapies with maintained or improved efficacy represents the primary unmet need, addressed by innovations like Susvimo’s continuous delivery and extended dosing formulations. Early detection challenges persist, as vision loss can be rapid and irreversible once wet AMD develops, necessitating improved screening and diagnostic approaches.

Beyond demographic trends, several factors accelerate market growth and innovation. Healthcare provider specialization and the establishment of dedicated retinal clinics improve patient access and treatment quality. Technological advances in injection techniques and monitoring systems enhance safety and efficacy while reducing complications. Patient advocacy organizations and educational initiatives increase disease awareness and treatment compliance. Regulatory pathway evolution, including breakthrough therapy designations and adaptive clinical trial designs, accelerates innovative therapy development and approval timelines.

High treatment costs represent the most significant barrier to optimal patient care, with annual treatment expenses reaching tens of thousands of dollars per patient. Limited access to retinal specialists, particularly in rural and underserved areas, creates geographic disparities in care quality. Treatment burden associated with frequent injections leads to patient non-compliance and suboptimal outcomes. Reimbursement complexities and prior authorization requirements delay treatment initiation and create administrative burdens. Manufacturing and supply chain challenges for complex biologics can impact product availability and pricing sustainability.

Connect with leading retinal specialists and market intelligence experts to understand treatment paradigm evolution and commercial opportunities in the Wet AMD treatment landscape.

Last Key Opinion Leader’s Perspective on Wet Age-Related Macular Degeneration Market

“The wet AMD treatment landscape has evolved remarkably over the past two decades, transforming from a condition with limited options to one with multiple effective anti-VEGF therapies. However, significant challenges remain, particularly regarding treatment burden and the need for frequent injections. The emergence of continuous delivery systems like Susvimo represents a paradigm shift that could dramatically improve patient quality of life and long-term outcomes. As we look forward, the integration of novel pathways like IL-6 inhibition and the development of gene therapies hold promise for achieving superior durability and efficacy. The key to success will be balancing innovation with cost-effectiveness while ensuring broad patient access to these life-changing treatments.” – Leading Retinal Specialist, Academic Medical Center

Conclusion

DelveInsight’s comprehensive analysis reveals that the wet AMD market is entering a transformative phase characterized by technological convergence and demographic acceleration. Our proprietary modeling indicates that successful therapies must demonstrate not only clinical differentiation but also address the critical treatment burden that affects patient compliance and long-term outcomes. The market’s evolution toward value-based care models creates opportunities for premium pricing for truly differentiated products while challenging traditional commercial approaches. Strategic market entry requires understanding of complex reimbursement landscapes, physician adoption patterns, and patient preference evolution toward longer-acting and more convenient treatment modalities.

Scope of the Wet Age-Related Macular Degeneration Market Report

• The report covers a comprehensive analysis of key market events, executive summary, and descriptive overview of Wet Age-Related Macular Degeneration, explaining its causes, signs and symptoms, pathophysiology, and currently available therapeutic interventions across the treatment landscape.

• Comprehensive epidemiological insights encompass forecasted patient populations, disease progression patterns, geographic distribution across the 7MM, age-specific segmentation analysis, and type-specific diagnosed prevalent cases distinguishing wet AMD from dry AMD manifestations.

• Detailed therapeutic assessment includes analysis of current and emerging treatment modalities, market share distribution of individual therapies, clinical efficacy and safety profiles, dosing regimens and administration routes, and comparative analysis of mechanism of action approaches across anti-VEGF and novel pathway inhibitors.

• Market dynamics analysis covers current and forecasted 7MM market size from 2020-2034, competitive landscape assessment, drug uptake patterns and adoption curves, pricing strategies and reimbursement considerations, and geographic market penetration analysis across the United States, EU4 countries, United Kingdom, and Japan.

• Pipeline intelligence encompasses comprehensive analysis of late-stage development programs, regulatory designations including breakthrough therapy and fast track status, clinical trial design and endpoints, development milestones and expected timelines, and partnership and collaboration activities across industry participants.

• Strategic analysis incorporates SWOT assessment of market opportunities and threats, qualitative conjoint analysis of competing therapies, unmet medical needs identification, treatment paradigm evolution analysis, and market access considerations including reimbursement policies and patient assistance programs.

• Industry insights feature key opinion leader perspectives on treatment landscape evolution, patient journey mapping and care pathway analysis, technology adoption patterns, and future therapeutic trends including gene therapy, sustained-release systems, and combination approaches.

• Commercial intelligence includes detailed company profiles of key market participants, product lifecycle management strategies, launch preparation activities, market access and pricing strategies, and competitive positioning analysis across established and emerging players in the wet AMD therapeutic space.

Table of Contents

1. Key Insights

2. Executive Summary of Wet AMD

3. Competitive Intelligence Analysis for Wet AMD

4. Wet AMD Market Overview at a Glance

5. Wet AMD: Disease Background and Overview

6. Wet AMD Patient Journey

7. Wet AMD Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Wet AMD Unmet Needs

10. Key Endpoints of Wet AMD Treatment

11. Wet AMD Marketed Products

12. Wet AMD Emerging Therapies

13. Wet AMD: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Wet AMD

17. KOL Views

18. Wet AMD Market Drivers

19. Wet AMD Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About DelveInsight

DelveInsight is a leading healthcare business research and consulting company that provides comprehensive market intelligence, competitive analysis, and strategic advisory services to pharmaceutical, biotechnology, and medical device companies worldwide. With deep expertise in therapeutic area analysis and commercial strategy, DelveInsight empowers industry leaders to make informed decisions and capitalize on emerging market opportunities.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services